



ASX Announcement and Media Release

Wednesday 23 September 2015

SciGen Ltd

SciGen Ltd and its holding Company Bioton SA Terminate the Distribution Agreement for Human Insulin in China

The Board of Directors of SciGen Limited (ASX:**SIE**) ("**SciGen**") announce that on 23 September 2015, SciGen, Bioton S.A ("**Bioton**") and Bayer Healthcare Company Limited ("**BHC**") entered into a Termination Agreement regarding the termination of all the agreements binding on such parties and executed prior to the date of the Termination Agreement, effective from 31 December 2015, including specifically the Agreement of 9 July 2009 executed between the SciGen, Bioton and BHC, regarding, inter alia, the delivery and distribution of human insulin within the territory of the People's Republic of China;

In connection with the joint decision to terminate the above-mentioned agreements, the parties also resolved that in the interim period, i.e. between the date of execution of the Termination Agreement and 31 December 2015 (effective date), they will continue to perform all the obligations envisaged in the agreements and will settle all their mutual liabilities.

About SciGen

SciGen Ltd is a progressive biopharmaceutical company involved in co-developing and marketing genetically engineered biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes therapeutics such as rhuman Growth Hormone, rhuman Insulin and GCSF.

SciGen has acquired the rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen's portfolio currently includes proprietary biotechnology-derived products, and biosimilar products, which allows for faster entry into the market, as the biogeneric products have undergone much of the clinical development and trials required to bring new drugs to market. This minimises the risks associated with early stage product development.

SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.

SciGen's major strength lies in its ability to recognise the potential of new products in their early stages of development. Through joint collaboration with its strategic partners, SciGen uses its extensive expertise in regulatory and clinical environments, in conjunction with marketing and promotional infrastructure, to bring to market products which will have significant long-term benefit.

SciGen's business was established in 1988. SciGen is a Singapore biotechnology company, publicly listed on the Australian Stock Exchange (ASX code SIE). SciGen's headquarters is in Singapore and it also has subsidiary companies and offices in Australia, South Korea, China and Philippines, distribution channels in China, India, Malaysia, Myanmar, Pakistan, Thailand and Indonesia and a contract manufacturer in Poland, Bioton S.A.

| For further information: Company - Investor Relations | Company |
|--|--|
| Ms. Gillian Dunlop SciGen (Australia) Pty Ltd +61 2 9485 1800 Email: gdunlop@scigen.com.au | Slawomir Ziegert CEO SciGen Ltd +65 6779 6638 |